June 17, 2003
By Lisa Ellis
InteliHealth Staff Writer
NEW ORLEANS The second part of a
major study aimed at finding a way to prevent
type 1 diabetes has produced disappointing results,
researchers announced.
No more than 10 percent of people
with diabetes have type 1. It stems from an immune
reaction that causes the body to destroy some of its own
cells in this case, the beta cells in the pancreas
that make insulin.
The medical community understands
pretty well how to prevent
type 2, the much more common type of diabetes.
Maintaining a normal weight and getting regular exercise
often can head off the disease, although family history
also makes a difference.
Type 1 can be prevented, too but so
far not in humans. Researchers have discovered 120
different ways to protect laboratory mice from the
disease, said Jay Skyler, M.D., a principal researcher
on the type 1 prevention study.
Relatives of people with type 1
diabetes have 10 to 20 times the average risk of
developing type 1 themselves.
Investigators in the study, called
the Diabetes Prevention Trial-Type 1 (DPT-1), identified
and tested more than 100,000 relatives of people with
type 1, in an attempt to find a way to protect them.
Several hundred agreed to participate in the study.
Researchers reported their first
results at the American Diabetes Association (ADA)
Scientific Sessions in 2001. In this part of the study,
relatives who faced the highest risk took insulin
injections in an attempt to head off diabetes.
The treatment did not work. People
who took the injections developed diabetes at virtually
the same rate as a control group who did not.
At the ADA's current meeting, Dr.
Skyler presented the outcome of a related study that
tried to prevent diabetes in 372 relatives with somewhat
lower risk.
Researchers did not want them to have
to get insulin injections, said Dr. Skyler, director of
endocrinology, diabetes and metabolism at the University
of Miami. So instead they received insulin pills.
Insulin given as a pill does not
lower blood sugar. Insulin, a protein, is digested by
the stomach and never reaches the bloodstream. But
reducing sugar was not the aim in this case, Dr. Skyler
said.
Instead, researchers hoped to trigger
reactions in the immune system that might stop the
destruction of the beta cells in the pancreas.
It didn't work, Dr. Skyler said.
People who took the insulin pills developed diabetes at
the same rate 35 percent within five years as those
who received a placebo, or fake pill.
This is the third large study that
attempted to prevent type 1 diabetes, said Joseph I.
Wolfsdorf, M.D., director of the Diabetes Program at
Children's Hospital Boston.
Because many participants were
children, investigators may have erred on the side of
safety by giving too small a dose of injected insulin,
said Dr. Wolfsdorf, a DPT-1 investigator and associate
professor of pediatrics at Harvard Medical School.
The DPT-1 study is not completely
over, however. Investigators are enrolling new possible
participants, and they plan to begin testing other
agents that potentially may prevent type 1 diabetes.